Compare Essex Property Trust, Inc. (ESS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Essex Property Trust, Inc. trades at $271.57 (market cap $17.26B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Essex Property Trust, Inc. is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ESS | XBI | |
|---|---|---|
Market Cap | $17.26B | $10.11B |
Volume | 454,464 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $298.33 | $169.55 |
52-Week Low | $239.61 | $104.99 |
Typical Hold Time | 111 Days | 38 Days |
Enterprise Value | $23.86B | — |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.58, up 0.2% on the day, amid a bearish technical signal but with mixed fundamental performance. Recent earnings show volatility with a Q2 2026 miss but a Q1 2026 beat, while revenue growth remains steady. The company maintains strong profitability margins and recently resolved litigation, improving its risk profile. Analyst consensus is a 'Buy' with a $303.41 price target, indicating potential upside from current levels.
The outlook for ESS is cautiously optimistic, supported by raised full-year guidance and institutional buying interest. Key opportunities include operational efficiency and dividend stability, but risks involve earnings inconsistency, high debt levels, and economic sensitivity. Investors should weigh solid fundamentals against technical bearishness and market volatility.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
